Trump tariff pressure: AstraZeneca to move production to US, announces $50 billion manufacturing push
AstraZeneca is set to invest $50 billion in the U.S., featuring a large manufacturing plant in Virginia, marking its biggest manufacturing investment. This move aligns with the company's expectation that 50% of its revenue will come from the U.S. by 2030. The decision comes amid rising tariff pressures from the Trump administration, aiming to bolster domestic drug supply chains.
AstraZeneca is set to invest $50 billion in the U.S., featuring a large manufacturing plant in Virginia, marking its biggest manufacturing investment. This move aligns with the company's expectation that 50% of its revenue will come from the U.S. by 2030. The decision comes amid rising tariff pressures from the Trump administration, aiming to bolster domestic drug supply chains.
